204 related articles for article (PubMed ID: 22507813)
1. Thrombosis in myeloproliferative and myelodysplastic syndromes.
Landolfi R; Di Gennaro L
Hematology; 2012 Apr; 17 Suppl 1():S174-6. PubMed ID: 22507813
[TBL] [Abstract][Full Text] [Related]
2. [Pathogenesis of thrombotic and hemorrhagic complications in myeloproliferative and myelodysplastic syndromes].
Vlădăreanu AM; Popov V; Bumbea H; Ciufu C; Vasilache V; Petre A; Onisâi M
Rev Med Chir Soc Med Nat Iasi; 2011; 115(1):14-9. PubMed ID: 21688554
[TBL] [Abstract][Full Text] [Related]
3. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation.
Landolfi R; Di Gennaro L; Falanga A
Leukemia; 2008 Nov; 22(11):2020-8. PubMed ID: 18800144
[TBL] [Abstract][Full Text] [Related]
4. Thrombosis in myeloproliferative neoplasms.
Falanga A; Marchetti M
Semin Thromb Hemost; 2014 Apr; 40(3):348-58. PubMed ID: 24610470
[TBL] [Abstract][Full Text] [Related]
5. Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies.
Landolfi R; Di Gennaro L; Novarese L; Patrono C
Semin Thromb Hemost; 2006 Apr; 32(3):251-9. PubMed ID: 16673279
[TBL] [Abstract][Full Text] [Related]
6. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
7. Are MPNs vascular diseases?
Finazzi G; De Stefano V; Barbui T
Curr Hematol Malig Rep; 2013 Dec; 8(4):307-16. PubMed ID: 24037420
[TBL] [Abstract][Full Text] [Related]
8. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; Neumann HA; van Vliet HH
Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
[TBL] [Abstract][Full Text] [Related]
9. Renal disease associated with myeloproliferative neoplasms and myelodysplastic syndrome/myeloproliferative neoplasms.
Büttner-Herold M; Sticht C; Wiech T; Porubsky S
Histopathology; 2021 Apr; 78(5):738-748. PubMed ID: 33078472
[TBL] [Abstract][Full Text] [Related]
10. [Mixed myelodysplastic and myeloproliferative syndromes].
Neuwirtová R; Mociková K; Jelínek J; Musilová J; Havlícek F; Adamkov M; Michalová K; Cermák J; Jonásová A; Smolíková A; Straub J; Tothová E; Voglová J; Vozobulová V; Waltrová L
Cas Lek Cesk; 1997 Dec; 136(23):724-9. PubMed ID: 9476375
[TBL] [Abstract][Full Text] [Related]
11. [What vascular events suggest a myeloproliferative disorder?].
Hachulla E; Rose C; Trillot N; Caulier-Leleu MT; Pasturel-Michon U
J Mal Vasc; 2000 Dec; 25(5):382-387. PubMed ID: 11148402
[TBL] [Abstract][Full Text] [Related]
12. How I Manage Thrombotic/Thromboembolic Complications in Myeloproliferative Neoplasms.
Koschmieder S
Hamostaseologie; 2020 Feb; 40(1):47-53. PubMed ID: 32050290
[TBL] [Abstract][Full Text] [Related]
13. [Thrombotic risk in myeloproliferative neoplasms: what the general practitioner needs to know].
Casini A; Boehlen F; Lecompte T; de Moerloose P
Rev Med Suisse; 2013 Feb; 9(372):315-8, 320. PubMed ID: 23469399
[TBL] [Abstract][Full Text] [Related]
14. Prevention and Management of Thrombosis in BCR/ABL-Negative Myeloproliferative Neoplasms.
Falanga A; Marchetti M; Schieppati F
Hamostaseologie; 2021 Feb; 41(1):48-57. PubMed ID: 33588455
[TBL] [Abstract][Full Text] [Related]
15. Clinical insights into the origins of thrombosis in myeloproliferative neoplasms.
Moliterno AR; Ginzburg YZ; Hoffman R
Blood; 2021 Mar; 137(9):1145-1153. PubMed ID: 33237986
[TBL] [Abstract][Full Text] [Related]
16. Prevention of recurrent thromboembolism in myeloproliferative neoplasms: review of literature and focus on direct oral anticoagulants.
How J; Story C; Connors JM
Postgrad Med; 2021 Jun; 133(5):508-516. PubMed ID: 33480813
[TBL] [Abstract][Full Text] [Related]
17. Relation of platelet abnormalities to thrombosis and hemorrhage in chronic myeloproliferative disorders.
Wehmeier A; Südhoff T; Meierkord F
Semin Thromb Hemost; 1997; 23(4):391-402. PubMed ID: 9263357
[TBL] [Abstract][Full Text] [Related]
18. How to manage thrombosis in myeloproliferative neoplasms.
Barbui T
Curr Opin Oncol; 2011 Nov; 23(6):654-8. PubMed ID: 21986846
[TBL] [Abstract][Full Text] [Related]
19. Erythromelalgia--a thrombotic complication in chronic myeloproliferative disorders.
Tarach JS; Nowicka-Tarach BM; Matuszek B; Nowakowski A
Med Sci Monit; 2000; 6(1):204-8. PubMed ID: 11208311
[TBL] [Abstract][Full Text] [Related]
20. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F.
Tefferi A; Elliott M
Semin Thromb Hemost; 2007 Jun; 33(4):313-20. PubMed ID: 17525888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
